Bengaluru — Johnson & Johnson (J&J) beat quarterly profit estimates on higher sales at its pharmaceuticals unit even as it faces fierce competition for some of its biggest drugs, sending the company’s shares up more than 2%. Sales from the business, which accounts for more than half of the company’s total revenue, rose 4.1% and beat estimates, mainly boosted by demand for Stelara — its treatment for psoriasis and Crohn’s disease — as well as cancer drugs Darzalex and Imbruvica. “J&J’s first-quarter results reflect another stellar quarter in pharma despite significant generic/biosimilar headwinds and continued progress in medical devices,” Cowen & Co analyst Joshua Jennings said. J&J’s medical device unit, its second-largest business, reported a 4.6% fall in sales but beat analysts’ average estimate of $6.44 bn. The unit has been struggling with slow growth of its spine and hip business, and the drug maker has been selling off some underperforming businesses.

Sales of Stelara...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now